Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
R Ella, KM Vadrevu, H Jogdand, S Prasad…�- The Lancet Infectious�…, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist�…
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist�…
COVID-19 vaccines:“Warp Speed” needs mind melds, not warped minds
JP Moore, PJ Klasse�- Journal of virology, 2020 - Am Soc Microbiol
In this review, we address issues that relate to the rapid “Warp Speed” development of
vaccines to counter the COVID-19 pandemic. We review the antibody response that is�…
vaccines to counter the COVID-19 pandemic. We review the antibody response that is�…
A paradox approach to societal tensions during the pandemic crisis
COVID-19 isn't going away soon [..] By now we know [...] that the novel Coronavirus will be
with us for a rather long time.[...] In the interest of managing our expectations and governing�…
with us for a rather long time.[...] In the interest of managing our expectations and governing�…
[HTML][HTML] Vacuna frente al COVID-19
JJ Picazo�- Revista Espa�ola de Quimioterapia, 2021 - ncbi.nlm.nih.gov
La pandemia por COVID-19 ha producido en nuestra sociedad un colapso sanitario,
econ�mico y psicol�gico enorme. Los sanitarios han tenido que enfrentarse a uno de los�…
econ�mico y psicol�gico enorme. Los sanitarios han tenido que enfrentarse a uno de los�…
[HTML][HTML] Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected�…
N Tormo, D Navalpotro, M Mart�nez-Serrano…�- …�and Infectious Disease, 2022 - Elsevier
We analysed immunological response during vaccination by using quantitative anti-spike
IgG antibodies (qAbs) and Interferon-gamma (IFNγ) production by SARS-CoV-2-specific�…
IgG antibodies (qAbs) and Interferon-gamma (IFNγ) production by SARS-CoV-2-specific�…
Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion InactivatedSARS-CoV-2 vaccine-BBV152
B Ganneru, H Jogdand, VK Dharam, NR Molugu…�- BioRxiv, 2020 - biorxiv.org
We report the development and evaluation of safety and immunogenicity of a whole virion
inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel�…
inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel�…
A meta-analysis of rhesus macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), African green monkeys (Chlorocebus aethiops), and ferrets�…
AN Witt, RD Green, AN Winterborn�- Comparative Medicine, 2021 - ingentaconnect.com
Animal models are at the forefront of biomedical research for studies of viral transmission,
vaccines, and pathogenesis, yet the need for an ideal large animal model for COVID-19�…
vaccines, and pathogenesis, yet the need for an ideal large animal model for COVID-19�…
[HTML][HTML] Case report: recurrent clinical symptoms of COVID-19 in healthcare professionals: a series of cases from Brazil
CFV Takeda, MM de Almeida…�- The American Journal�…, 2020 - ncbi.nlm.nih.gov
We describe six cases of healthcare professionals in Brazil who recovered but again
presented symptoms consistent with COVID-19, with new positive reverse transcription (RT)�…
presented symptoms consistent with COVID-19, with new positive reverse transcription (RT)�…
A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152
R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy…�- MedRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double�…
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double�…
[HTML][HTML] Comparing and contrasting MERS, SARS-CoV, and SARS-CoV-2: prevention, transmission, management, and vaccine development
The COVID-19 pandemic is responsible for an unprecedented disruption to the healthcare
systems and economies of countries around the world. Developing novel therapeutics and a�…
systems and economies of countries around the world. Developing novel therapeutics and a�…